Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelics Industry News Stories for the Week of July 20th – 26th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
10. FDA and Psychedelics: What it Has, What it Wants
Any New Drug Therapy That Can Be Manufactured and Sold in the U.S. Has to Have the Approval of the FDA. That’s the Deal
Recently, the FDA has had to face a perplexing issue with plant-based Psychedelic substances that have found new meaning within the health and wellness community—Cannabis, Psilocybin, MDMA, Ketamine and LSD.
READ FULL FDA ARTICLE
9. Red White & Bloom to Acquire Premium Cannabis Brand with Over Million in Annualized Revenue
Platinum Vape Boasts an Annualized Revenue Run Rate of Over USD $70 Million and EBITDA of Between $17.5 Million to $21 Million
Red White & Bloom (OTCQX: RWBYF) announced the signing of a binding LOI to acquire a group of California-based companies operating under the name Platinum Vape. Platinum Vape currently has its premium products, including vapes, flower, edibles and pre-rolls in over 700 retail locations across Michigan, California and Oklahoma.
READ FULL RWB PLATINUM VAPE ARTICLE
8. Champignon Brands Files Business Acquisition Reports and Appoints New Director
Champignon Also Announced the Appointment of Company CEO, Dr. Roger McIntyre, to its Board of Directors
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced on Friday it filed the required Business Acquisition Reports (BAR) in relation to the company’s previously announced acquisitions of Artisan Growers, Novo Formulations and Tassili Life Sciences. Dr. McIntyre will replace Pat McCutcheon as a director on the company’s board. Mr. McCutcheon, CEO of MediPharm Labs (OTCQX: MEDIF), will remain with the company in an advisory capacity, which will permit him increased mobility to assist Champignon with ongoing and planned capital markets initiatives.
READ FULL CHAMPIGNON ARTICLE
7. Illinois Sees Record-Breaking Legal Cannabis Sales, Providing a Range of Social and Economic Benefits
There’s No Denying it, the Green Brings in the Green and the Land of Lincoln is Rollin’ in the Benjamins
Last week, the governor of Illinois announced that the state brought in $52 million in tax revenue in the first six months of legal recreational Cannabis sales. During that same time period, total Marijuana sales amounted to $239 million.
READ FULL ILLINOIS ARTICLE
6. Psychedelics Are Making a Wild Comeback – Let’s Not Eff it Up
The Consciousness-Raising Power of Psychedelics Are Tripping up Science Once Again – Hopefully, We’re Not Headed for a Refried Version of Legal Weed
Johns Hopkins University, the U.S. Food and Drug Administration (FDA), research projects funded by billionaire tycoons and Silicon Valley bros micro-dosing Magic Mushrooms to boost productivity, the potential therapeutic benefits of Psychedelics – Psilocybin, LSD, MDMA and DMT (Ayahuasca), you name it – are shaking up science again.
READ FULL PSYCHEDELICS COMEBACK ARTICLE
5. FDA Submits CBD Enforcement Policy Draft Guidance to White House
Federal Food and Drug Officials Submitted a CBD Enforcement Policy Document for Approval on Wednesday, Meaning That Long-Awaited Industry Guidance on CBD is Nearing
The U.S. Food and Drug Administration (FDA) submitted its Cannabidiol Enforcement Policy Draft Guidance for Industry to the White House Office of Management and Budget.
READ FULL FDA CBD ARTICLE
4. Psychedelics Activists Unveil Measure to Legalize Plant Medicine Healing Ceremonies in Oakland
Decriminalize Nature, the Group Behind the Ordinance, Submitted it Last Week to Councilmember Noel Gallo (D)
Psychedelics activists have released a proposed measure to allow Oakland, California residents to use a variety of entheogenic substances in plant medicine healing ceremonies. Noel Gallo (D) previously sponsored Decriminalize Nature’s now-enacted measure to deprioritize enforcement of laws against certain plants and fungi such as Psilocybin mushrooms and Ayahuasca.
READ FULL OAKLAND PSYCHEDELICS ARTICLE
3. Cannabis Demand at All-Time High Amid Pandemic, Curaleaf Says
Consumers Are Buying Record Amounts of Cannabis Amid the Covid-19 Pandemic, According to the Chairman of Curaleaf
U.S. multi-state operator (MSO) Curaleaf (OTCQX: CURLF), which just completed its purchase of Grassroots, saw its highest-ever monthly sales in June, Boris Jordan said in an interview. July is shaping up to be another record, even before the acquisition is factored in, he said.
READ FULL CANNABIS DEMAND ARTICLE
2. Ease Restrictions on Medical Psychedelics to Aid Research, Experts Say
Psilocybin May Be Safe for Treating Depression But Research is Stymied By Government Controls
Potential treatments for severe depression, addiction and other mental health disorders are being held up by excessive restrictions on Psilocybin, the active ingredient in Magic Mushrooms, scientists and politicians have said.
READ FULL MEDICAL PSYCHEDELICS ARTICLE
1. Congress Planning Vote on Federal Marijuana Legalization Bill in September
House Leadership is Moving Toward Holding a Floor Vote on a Comprehensive Federal Cannabis Legalization Bill in September
The Marijuana Opportunity, Reinvestment and Expungement (MORE) Act—introduced by Judiciary Committee Chairman Jerrold Nadler (D-NY) last year—has already cleared his panel and was referred to several other committees. In the months since advocates have been eagerly awaiting further action to advance the legislation to the floor.
READ FULL CANNABIS LEGALIZATION ARTICLE
Photo by ryan lange on Unsplash
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
